natgillin/translations-raw huggingface dataset:
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic (PK) interactions.
Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
Reye's syndrome is a very rare disease which can be fatal.
Reyev sindrom je zelo redka bolezen, ki je lahko smrtna.
• anti-retroviral medicines (medicines used to treat HIV infections)
• protiretrovirusna zdravila (zdravila za zdravljenje okužbe z virusom HIV),
In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
V klinični študiji, izvedeni pri zdravih osebah, klopidogrel ni zahteval spremembe odmerka heparina ali spremenil učinka heparina na koagulacijo.
Other concomitant therapy with clopidogrel
Drugo sočasno zdravljenje s klopidogrelom
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
Specifične farmakokinetične študije, izvedene z radioaktivno označenim klopidogrelom, so pokazale, da se matična spojina ali njeni metaboliti izločajo v mleko.
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥ 60 let (26 % ≥ 70 let) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
Uricosurics (benzbromarone, probenecid, sulfinpyrazone) Caution is required because ASA may inhibit the effect of uricosuric agents through competitive elimination of uric acid.
Urikozuriki (benzbromaron, probenecid, sulfinpirazon) Potrebna je previdnost, kajti ASA lahko zavre učinek urikozuričnih zdravil s kompetitivno eliminacijo sečne kisline.
Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration dependent (nonlinear).
Njen presnovek, salicilna kislina, je v veliki meri vezana na beljakovine v plazmi, vendar je njena vezava odvisna od koncentracije (nelinearna).
With moderate intoxication an attempt can be made to induce vomiting; if this fails, gastric lavage is indicated.
V primeru zmerne zastrupitve je mogoče poskusiti izzvati bruhanje; če to ne uspe, je indicirano izpiranje želodca.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da klopidogrela med nosečnostjo ne uporabljate.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• preobčutljivosti na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1,
Therefore, such addition should be undertaken with caution outside of clinical situations where the combination has proven to be beneficial.
To kombinacijo je zato izven kliničnih stanj, pri katerih se je izkazala za učinkovito, potrebno uporabiti s previdnostjo.
Biotransformation and Elimination
Biotransformacija in izločanje:
Reproduction toxicity data show that ASA is teratogenic in several laboratory animals.
Podatki o vplivu na sposobnost razmnoževanja kažejo teratogenost ASA pri več laboratorijskih živalih.
Although the clinical relevance of these findings is uncertain, there have been spontaneous reports of HIV-infected patients treated with boosted ART, who have experienced re-occlusive events after de-obstruction or have suffered thrombotic events under a clopidogrel loading treatment schedule.
Čeprav je klinični pomen teh opažanj negotov, obstajajo spontana poročila o bolnikih, okuženih z virusom HIV, zdravljenih z okrepljenim protiretrovirusnim zdravljenjem, ki so doživeli ponovne okluzivne dogodke po odpravi obstrukcije ali so doživeli trombotične dogodke med zdravljenjem s polnilnim odmerkom klopidogrela.
If you forget for more than 12 hours, simply take the next single dose at the usual time.
Če tableto pozabite za več kot 12 ur, preprosto vzemite naslednjo tableto ob običajnem času.
There is a possible association between acetylsalicylic acid (ASA) and Reye's Syndrome when products containing ASA are given to children or adolescents with a viral infection.
Obstaja možna povezava med acetilsalicilno kislino (ASA) in Reyevim sindromom, če otroci ali mladostniki dobijo zdravila z ASA pri virusni okužbi.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
• aktivne patološke krvavitve, kot je peptična razjeda ali intrakranialna krvavitev.
Overall clopidogrel 75 mg/day was similar to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE podoben ASA v odmerku 325 mg/dan, ne glede na starost, spol ali raso.
A pharmacodynamic interaction between Clopidogrel/Acetylsalicylic acid Mylan and heparin is possible, leading to increased risk of bleeding.
Farmakodinamična interakcija med zdravilom Klopidogrel/acetilsalicilna kislina Mylan in heparinom je možna in vodi do povečanega tveganja za krvavitev.
The following symptoms can also arise: hyperthermia and perspiration, leading to dehydration, restlessness, convulsions, hallucinations and hypoglycaemia.
Pojavijo se lahko tudi naslednji simptomi: hipertermija in znojenje, ki povzroči dehidracijo, nemir, konvulzije, halucinacije in hipoglikemija.
Reye's Syndrome is a very rare disease which can be fatal.
Reyev sindrom je zelo redka bolezen, ki pa je lahko smrtna.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel plus ASA group and 363 (5.8%) in the ASA group].
Ta korist je bilav glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom in ASA, in 363 (5,8 %) v skupini z ASA].
Mylan Hungary Kft, H-2900 Komárom, Mylan utca 1, Hungary.
Mylan Hungary Kft, H-2900 Komárom, Mylan utca 1, Madžarska
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
V raziskavi CURE je 823 (6,6 %) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
• In patients with gout since low doses of ASA increase urate concentrations.
• Pri bolnikih s protinom, ker majhni odmerki ASA povečujejo koncentracijo urata.
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
Podatki epidemioloških študij kažejo večje tveganje spontanih splavov, malformacij srca in gastroshize po uporabi zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
Therefore, this combination should be used with caution in patients taking low dose ASA for cardioprotection.
Zato je to kombinacijo treba uporabljati previdno pri bolnikih, ki jemljejo nizke odmerke acetilsalicilne kisline za zaščito srca.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Trombotična trombocitopenična purpura (TTP) Zelo redko so po uporabi klopidogrela poročali o trombotični trombocitopenični purpuri (TTP), ki se je včasih pojavila že po kratki izpostavljenosti.
Apart from the specific medicinal product interaction information described above, interaction studies with Clopidogrel/Acetylsalicylic acid Mylan and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Razen navedenih informacij o specifičnih interakcijah z zdravili, študij o interakcijah zdravila Klopidogrel/acetilsalicilna kislina Mylan in nekaterih zdravil, ki jih pogosto uporabljajo bolniki z aterotrombotično boleznijo, ni bilo.
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 30,000 patients treated with clopidogrel plus ASA, and over 9,000 patients treated for 1 year or more.
Varnost klopidogrela so ocenili pri več kot 42.000 bolnikih, ki so sodelovali v kliničnih študijah; več kot 30.000 teh bolnikov je dobivalo kombinacijo klopidogrela in ASA, pri več kot 9.000 pa je zdravljenje trajalo 1 leto ali več.
Clopidogrel/Acetylsalicylic acid Mylan should not be used during the first two trimesters of pregnancy unless the clinical condition of the woman requires treatment with clopidogrel/ASA.
Zdravilo Klopidogrel/acetilsalicilna kislina Mylan se ne sme uporabljati v prvih dveh trimesečjih nosečnosti, razen če klinično stanje nosečnice ne zahteva terapije s klopidogrelom/ASA.
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4.
Aktivni presnovek nastane predvsem z delovanjem CYP2C19, k nastanku pa pripomorejo tudi drugi encimi CYP, vključno s CYP1A2, CYP2B6 in CYP3A4.
The de-escalated patients underwent high platelet reactivity (HPR) testing.
Bolniki z deeskaliranjem so opravili preskušanje visoke reaktivnosti trombocitov (HPRhigh platelet reactivity).
The safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila vrednotena pri bolnikih z akutnim miokardnim infarktom.
At high ASA doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher.
Pri velikih odmerkih ASA poteka odstranjevanje salicilne kisline s kinetiko ničelnega reda (tj. delež odstranjevanja je stalen glede na koncentracijo v plazmi); navidezni razpolovni čas je 6 ur ali več.
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development.
Zavrtje sinteze prostaglandinov lahko neugodno vpliva na nosečnost in/ali razvoj zarodka oz. ploda.
For minor cuts and injuries e.g., cutting yourself shaving, this is usually of no concern.
Pri manjših vrezninah ali poškodbah, npr. če se urežete pri britju, navadno ni razloga za skrb.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine.
Krvavitve se lahko pojavijo kot krvavitve v želodcu ali črevesju, podplutbe, hematomi (neobičajne krvavitve ali podplutbe pod kožo), krvavitev iz nosu, kri v urinu.
** Information related to clopidogrel with frequency “not known”.
Informacije v povezavi s klopidogrelom s pogostnostjo »ni znana«.
If patients must temporarily stop antiplatelet therapy, Clopidogrel/Acetylsalicylic acid Mylan should be discontinued 7 days prior to surgery.
Če mora bolnik začasno prekiniti antiagregacijsko terapijo, morate zdravilo Klopidogrel/acetilsalicilna kislina Mylan ukiniti 7 dni pred kirurškim posegom.
It is unknown whether clopidogrel is excreted in human breast milk.
Ni znano, ali se klopidogrel izloča v materinem mleku pri človeku.
The lethal dose of acetylsalicylic acid is 25-30 g. Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Smrtni odmerek acetilsalicilne kisline je od 25 do 30 g. Koncentracija salicilata v plazmi nad 300 mg/l (1,67 mmol/l) nakazuje zastrupitev.
Doses of 100-500 mg/day:
Odmerki od 100 do 500 mg/dan:
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).
Koristnosti zdravljenja s kombinacijo klopidogrela in ASA, ki bi bilo daljše od štirih tednov, v tem okviru niso preučevali (glejte poglavje 5.1).
Where elective surgery is being considered, the need for dual antiplatelet therapy should be reviewed and consideration given to the use of a single antiplatelet agent.
Če je predvidena elektivna operacija, je treba potrebo po dvotirnem antiagregacijskem zdravljenju ponovno pretehtati in v poštev pride uporaba enega samega antiagregacijskega zdravila.
Caution is recommended when co-administering salicylates with acetazolamide as there is an increased risk of metabolic acidosis.
Previdnost se priporoča pri sočasni uporabi salicilatov in acetazolamida, saj obstaja povečano tveganje za metabolično acidozo.
Adverse reactions that occurred with clopidogrel alone, with ASA alone or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Neželeni učinki, zabeleženi samo s klopidogrelom, samo z ASA ali s klopidogrelom v kombinaciji z ASA, v kliničnih študijah ali opisani spontano, so našteti v spodnji preglednici.
Mylan Hungary Kft, Mylan utca 1, Komárom, H-2900, Hungary.
Mylan Hungary Kft, H-2900 Komárom, Mylan utca 1, Komárom, H-2900, Madžarska.
• signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots, and/or confusion (see section 2 ‘Warnings and precautions').
• znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay and reduce the absorption of clopidogrel presumably because of slowed gastric emptying.
Tako kot to velja za druge peroralne zaviralce P2Y12, lahko sočasna uporaba opioidnih agonistov upočasni in zmanjša absorpcijo klopidogrela, verjetno zaradi upočasnitve praznjenja želodca.
• acetazolamide, a medicine used to treat glaucoma (increased ocular pressure) or epilepsy or to increase urine flow,
• acetazolamid, zdravilo za zdravljenje glavkoma (povišanega očesnega tlaka) ali epilepsije ali za povečanje pretoka urina,
Minor GI symptoms, such as dyspepsia, are common and can occur anytime during therapy.
Manj izraziti gastrointestinalni simptomi npr. dispepsija, so sicer pogosti in se lahko pojavijo kadar koli med zdravljenjem.
Based on the pharmacokinetic and metabolic characteristics of both compounds, clinically significant PK interactions are unlikely.
Glede na farmakokinetične in presnovne značilnosti obeh snovi klinično pomembne farmakokinetične interakcije niso verjetne.
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
Morda vam je zdravnik za zdravljenje vaše bolezni v zamašeno ali zoženo arterijo namestil žilno opornico (»stent«), da bi obnovil ustrezen pretok krvi.
A total of 99.7% of patients received fibrinolytics (fibrin-specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Skupno 99,7 % bolnikov je dobivalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % zaviralce adrenergičnih receptorjev beta, 54,7 % zaviralce ACE in 63 % statine.
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
- če imate bolečine v želodcu ali trebuhu ali krvavitev v želodec ali črevo (rdeče blato ali črno blato).
the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labour.
• mater in novorojenčka na koncu nosečnosti: - možnemu podaljšanju časa krvavitve, antiagregacijskemu učinku, ki se lahko pojavi celo po zelo majhnih odmerkih, - zavrtju krčenja maternice in zaradi tega odloženemu ali podaljšanemu porodu.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST spojnice sta bili varnost in učinkovitost klopidogrela vrednoteni v dveh randomiziranih, s placebom kontroliranih, dvojno slepih raziskavah, CLARITY in COMMIT.
In one study, when a single dose of ibuprofen 400 mg was taken within 8 hours before or within 30 minutes after immediate release aspirin dosing (81 mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred.
V eni študiji, v kateri je bil en enkraten odmerek 400 mg ibuprofena uporabljen v 8 urah pred ali v 30 minutah po zaužitju acetilsalicilne kisline s takojšnjim sproščanjem (81 mg), se je zmanjšal učinek acetilsalicilne kisline na nastajanje tromboksana in agregacijo trombocitov.
Glycoprotein IIb/IIIa inhibitors
Zaviralci glikoproteina IIb/IIIa
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
• če imate kakšno bolezen, ki trenutno povzroča krvavitev, npr. razjedo na želodcu ali krvavitev v možganih,
In patients with recent transient ischaemic attack or stroke who are at high risk of recurrent ischaemic events, the combination of ASA and clopidogrel has been shown to increase major bleeding.
Pri bolnikih z nedavnimi tranzitornimi ishemičnimi atakami (TIA) ali možgansko kapjo, pri katerih obstaja nevarnost ponavljajočih se ishemij, je kombinacija ASA in klopidogrela povečala hudo krvavitev.
If the use of Clopidogrel/Acetylsalicylic acid Mylan is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
V primeru prenehanja uporabe zdravila Klopidogrel/acetilsalicilna kislina Mylan lahko bolniku koristi nadaljevanje uporabe enega antiagregacijskega zdravila.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the pre- discharge angiogram, or death or recurrent MI before coronary angiography.
Primarni opazovani dogodki so bili navzočnost zamašene arterije (povezane z infarktom) na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
Low doses (up to 100 mg/day):
Nizki odmerki (do 100 mg/dan):
It is recommended that patients not be given salicylates for an interval of six weeks after receiving the varicella vaccine.
Priporočljivo je, da bolniki šest tednov po prejemu cepiva proti noricam ne jemljejo salicilatov.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
Če je potrebna takojšnja korekcija podaljšanega časa ASA krvavitve, lahko učinke klopidogrela odpravi transfuzija trombocitov.
Doses of 500 mg/day and above:
Odmerki 500 mg/dan in več:
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
Varnost in učinkovitost kombinacije klopidogrela in ASA sta bili vrednoteni v treh dvojno slepih raziskavah, v katere je bilo vključenih več kot 61.900 bolnikov: študije CURE, CLARITY in COMMIT, ki so primerjale kombinacijo klopidogrela in ASA s samo ASA; oboje so bolniki dobivali v kombinaciji z drugo standardno terapijo.
• if you have gout.
• če imate protin,
Driving and using machines Clopidogrel/Acetylsalicylic acid Mylan should not affect your ability to drive or to use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Klopidogrel/acetilsalicilna kislina Mylan ne bi smelo vplivati na vašo sposobnost za vožnjo ali upravljanje strojev.
Clopidogrel plus ASA significantly reduced the relative risk of death from any cause by 7% (p = 0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p = 0.002), representing an absolute reduction of 0.5% and 0.9%, respectively.
Klopidogrel in ASA sta pomembno zmanjšala relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p = 0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9 % (p = 0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
Concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in NSAID lahko poveča nevarnost ledvične okvare.
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na tableto, kar v bistvu pomeni ‘brez natrija'.
Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and foetal tissues.
Salicilna kislina se v veliki meri porazdeli po vseh telesnih tkivih in tekočinah, tudi v osrednjem živčevju, materinem mleku in plodovih tkivih.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel plus ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostalo (glejte poglavje 4.4).
• swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin.
• otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži.
• if you are allergic to other products called non-steroidal anti-inflammatory products usually used to treat painful and/or inflammatory conditions of muscles or joints.
• če ste alergični na druga zdravila, t. i. nesteroidna protivnetna zdravila, ki jih ponavadi uporabljamo za zdravljenje bolečin in/ali vnetja mišic ali sklepov,
In any case, you should take it for as long as your doctor continues to prescribe it.
Zdravilo morate jemati toliko časa, kot vam naroči zdravnik.
Due to the presence of both components of the medicinal product, Clopidogrel/Acetylsalicylic acid Mylan is contraindicated in case of:
Zaradi vsebnosti obeh učinkovin v zdravilu je zdravilo Klopidogrel/acetilsalicilna kislina Mylan kontraindicirano v primeru:
• Severe renal impairment (creatinine clearance <30 ml/min).
• pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min),
Clopidogrel/Acetylsalicylic acid Mylan is not intended for use in children or adolescents less than 18 years of age.
Zdravilo Klopidogrel/acetilsalicilna kislina Mylan ni namenjeno uporabi pri otrocih in mladostnikih, mlajših od 18 let.
During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes.
V predkliničnih študijah na podganah in pavijanih so bile jetrne spremembe najpogosteje opaženi učinek.
Activated charcoal (adsorbent) and sodium sulphate (laxative) are then administered.
Potem je treba uporabiti aktivno oglje (adsorbens) in natrijev sulfat (odvajalo).
Excipients with known effect Each film-coated tablet contains 48 mg of lactose.
Pomožne snovi z znanim učinkom Ena filmsko obložena tableta vsebuje 48 mg laktoze.
Patients with pre-existing mastocytosis, in whom the use of acetylsalicylic acid may induce severe hypersensitivity reactions (including circulatory shock with flushing, hypotension, tachycardia and vomiting).
Bolniki z (že) obstoječo mastocitozo, pri katerih lahko uporaba acetilsalicilne kisline povzroči resne preobčutljivostne reakcije (vključno s cirkulacijskim šokom z zardevanjem, hipotenzijo, tahikardijo in bruhanjem).
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo (približno 7 - 10 dni) in normalno delovanje trombocitov se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.